,Minimum Age,Maximum Age,Sex,Gender-based Eligibility,Gender Eligibility Description,Accepts Healthy Volunteers,Criteria,Study Population,Sampling Method
NCT05392712,18 Years,79 Years,All,,,Yes,"For healthy volunteers: Inclusion Criteria: Age 18-79 years old; No history of cardiovascular disease (coronary heart disease, structural heart disease, arrhythmia, heart failure, stroke, pulmonary embolism, aortic dissection, etc.), no cardiovascular risk factors (hypertension, diabetes, hyperlipidemia).
For people over 65 years old, those with hypertension or hyperlipidemia, but with well-controlled blood pressure and lipid levels, taking no more than 2 drugs, and echocardiography showing no left ventricular hypertrophy, can be included; The electrocardiogram is normal, and the cardiac ultrasound is basically normal in the past 1 year (mild valvular regurgitation can be included). Sign the informed consent. Exclusion Criteria: Those who with acute or chronic respiratory diseases; Those who with obvious abnormality of liver or kidney function; Those who with endocrine diseases such as abnormal thyroid function; Those who with anemia or other blood diseases; Those who with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.); Those who are obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2); Those who with malignant tumors; Those who with infectious diseases or infectious diseases; Those who with trauma or physical disability; Those who with psychological or mental illness such as depression; Those who are professional athletes, pregnant or breastfeeding women, alcoholics; Those who are unable to perform magnetocardiography examination due to claustrophobia, etc., or those who fail to receive magnetocardiography examination; Due to various reasons such as allergy to contrast agents, metal implants in vivo that are prohibited from performing 1.5T MRI (such as prostheses or steel plates implanted in orthopaedics, uterine contraceptive device) and other reasons, those who cannot or fail to cooperate with the corresponding research requirements. For chest pain patients who will undergo CAG or CTA: Inclusion Criteria: Age 18-79 years old; Those with chest pain symptoms, diagnosed or highly suspected by the attending doctor or above as stable angina pectoris (SA), unstable angina pectoris (UA), non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation myocardial infarction (STEMI), and plan to receive CAG or coronary CTA; Sign the informed consent. Exclusion Criteria: Patients with known structural heart disease such as cardiomyopathy and valvular disease; Patients with arrhythmias such as atrial fibrillation, supraventricular tachycardia, and atrioventricular block that have not returned to normal; History of other cardiovascular diseases such as pulmonary embolism and aortic dissection; Patients with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications; Obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply; Obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2); Patients with malignant tumors; Professional athletes, pregnant or breastfeeding women, alcoholics; Acute diseases or critical illnesses in other systems, such as acute or severe respiratory diseases, abnormal liver function or renal function, etc.; Patients with infectious diseases or infectious diseases; Those who are unable or fail to perform magnetocardiography due to claustrophobia, physical impairment, etc.; Unable to or fail to cooperate with the corresponding research requirements. For AMI patients: Inclusion Criteria: Age 18-79 years old; The attending doctor or above has diagnosed the patient as acute myocardial infarction (NSTEMI, STEMI), the condition of whom is relatively stable, and CMR examination is feasible after evaluation. Sign the informed consent. Exclusion Criteria: Patients with known structural heart disease such as cardiomyopathy and valvular disease; Patients with arrhythmias such as atrial fibrillation, supraventricular tachycardia, and atrioventricular block that have not returned to normal; History of other cardiovascular diseases such as pulmonary embolism and aortic dissection; Patients with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications; Obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply; Obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2); Patients with malignant tumors; Professional athletes, pregnant or breastfeeding women, alcoholics; Acute diseases or critical illnesses in other systems, such as acute or severe respiratory diseases, abnormal liver function or renal function, etc.; Patients with infectious diseases or infectious diseases; Those who are unable or fail to perform magnetocardiography due to claustrophobia, physical impairment, etc.; Due to various reasons such as allergy to contrast agents, metal implants in vivo that are prohibited from performing 1.5T MRI (such as prostheses or steel plates implanted in orthopaedics, uterine contraceptive device) and other reasons, those who cannot or fail to cooperate with the corresponding research requirements.",,
NCT04305366,18 Years,100 Years,All,,,Yes,Inclusion Criteria: Subjects between the ages of 18 and 100 Patients who are seen and evaluated by a provider within the adult ENT clinic at University of Colorado Hospital Patients that present with a current or past diagnosis of head and neck cancer -OR-Patients undergoing tonsillectomy or sleep surgery as standard of care (control group) Exclusion Criteria: Under the age of 18 or over the age of 100 Unwilling to participate,"Up to 500 patients will be enrolled in this study.
Subjects to be enrolled in this study will already have a clinical relationship with a professional in the adult ENT clinic at University of Colorado Hospital. This study will target patients with a diagnosis squamous cell carcinoma in the head and neck.
In addition, this study will also target patients undergoing tonsillectomy or sleep surgery as the control group.
This study will aim to enroll an equal number of patients into both the study group and control group.
However, this will be dependent on patient encounters within the adult ENT clinic.",Non-Probability Sample
NCT04368728,18 Years,85 Years,All,,,Yes,"Inclusion Criteria: Male or female participants between the ages of 18 and 55 years, inclusive, 65 and 85 years, inclusive, or 18 and 85 years, inclusive, at randomization (dependent upon study stage). Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures. Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study. Capable of giving personal signed informed consent Exclusion Criteria: Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV). History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s). Receipt of medications intended to prevent COVID 19. Stages 1 and 2 only: Previous clinical or microbiological diagnosis of COVID 19. Sentinel participants in Stage 1 only: Individuals at high risk for severe COVID-19, including those with any of the following risk factors: Hypertension Diabetes mellitus Chronic pulmonary disease Asthma Current vaping or smoking History of chronic smoking within the prior year BMI >30 kg/m2 Anticipating the need for immunosuppressive treatment within the next 6 months Sentinel participants in Stage 1 only: Individuals currently working in occupations with high risk of exposure to SARS-CoV-2 (eg, healthcare worker, emergency response personnel). Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. Women who are pregnant or breastfeeding. Previous vaccination with any coronavirus vaccine. Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation. Previous participation in other studies involving study intervention containing lipid nanoparticles. Sentinel participants in Stage 1 only: Positive serological test for SARS-CoV-2 IgM and/or IgG antibodies at the screening visit. Sentinel participants in Stage 1 only: Any screening hematology and/or blood chemistry laboratory value that meets the definition of a â‰¥ Grade 1 abnormality. Sentinel participants in Stage 1 only: Positive test for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (HBc Abs), or hepatitis C virus antibodies (HCV Abs) at the screening visit. Sentinel participants in Stage 1 only: SARS-CoV-2 NAAT-positive nasal swab within 24 hours before receipt of study intervention. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.",,
